Haemonetics (HAE) Tops Q3 EPS by 3c; Sees FY17 Outlook at High End of Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Barrington Research Downgrades Haemonetics (HAE) to Market Perform
February 7, 2017 9:33 AM ESTBarrington Research downgraded Haemonetics (NYSE: HAE) from Outperform to Market Perform and removed its price target (prior $41.00).
For an analyst ratings summary and ratings history on Haemonetics click here. For more ratings news on Haemonetics click here.
Shares of Haemonetics closed at $38.00 yesterday.
... More